The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

RRx-001, a clinical macrophage-stimulating anti-cancer agent that also produces nitric oxide (NO) was studied in a model of ischemia-reperfusion injury.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Expert Rev Hematol

Title: Expert review of hematology

Publisher: Informa UK Limited

ISSN (Electronic): 1747-4094

ISSN (Print): 1747-4094

Publication date (Electronic): May 22 2017

Affiliations

[1 ] a Department of Bioengineering , University of California San Diego (UCSD) , La Jolla , CA , USA.

[2 ] b EpicentRx , Mountain View , CA , USA.

[3 ] c InterWest Partners , Menlo Park , CA , USA.

[4 ] d Walter Reed Military Medical Center , Murtha Cancer Center , Bethesda , MD , USA.

[5 ] e Moores Cancer Center , University of California San Diego (UCSD) , La Jolla , CA , USA.

[6 ] f CFLS Data , San Jose , CA , USA.

Article

DOI: 10.1080/17474086.2017.1324779

PubMed ID: 28448172

SO-VID: cc7ed813-b219-43e6-aacc-a5f68d47458a

History

Keywords: Ischemia-reperfusion injury,RRx-001,functional capillary density,nitric oxide,oncology

Data availability:

Keywords: Ischemia-reperfusion injury, RRx-001, functional capillary density, nitric oxide, oncology

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.

Read this article at

Abstract

Related collections

Karger: Oncology

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 8